CLINICAL TRIALS PROFILE FOR FLURAZEPAM HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for flurazepam hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00283790 ↗ | Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo | Completed | Sanofi | Phase 4 | 2006-01-01 | Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator |
| NCT02350309 ↗ | Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder | Completed | Eisai Inc. | Phase 1 | 2014-12-13 | This is a single-dose, randomized, placebo-controlled, 3-way crossover study of 2 dosage strengths of lemborexant (5 mg and 10 mg) in participants with insomnia disorder. |
| NCT02374567 ↗ | Pharmacovigilance in Gerontopsychiatric Patients | Terminated | Hannover Medical School | Phase 3 | 2015-01-01 | The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data. |
| NCT03708341 ↗ | Exogenous Melatonin in Intensive Care Unit Chronodisruption | Unknown status | Saint-Joseph University | Phase 3 | 2018-11-15 | To this day, a small number of studies have evaluated the effect of melatonin on the modifications of the characteristics of sleep in critical care units, with mostly a small studied population. However, no study has been realized on a large population, nor has it evaluated the association between genetic factors and response to treatment (melatonin), hence the originality of our study. In our study we hypothesized that systematic melatonin usage in ICU can ameliorate the total sleep time and the fragmentation index and can decrease the confusion related to sleep deprivation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for flurazepam hydrochloride
Condition Name
Clinical Trial Locations for flurazepam hydrochloride
Trials by Country
Clinical Trial Progress for flurazepam hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for flurazepam hydrochloride
Sponsor Name
